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Virtual clinical trials identify 
effective combination therapies  
in ovarian cancer
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Anniina färkkilä1,5,6,7* & Sampsa Hautaniemi1,7*
A major issue in oncology is the high failure rate of translating preclinical results in successful clinical trials. 
Using a virtual clinical trial simulations approach, we present a mathematical framework to estimate 
the added value of combinatorial treatments in ovarian cancer. This approach was applied to identify 
effective targeted therapies that can be combined with the platinum-taxane regimen and overcome 
platinum resistance in high-grade serous ovarian cancer. We modeled and evaluated the effectiveness of 
three drugs that target the main platinum resistance mechanisms, which have shown promising efficacy 
in vitro, in vivo, and early clinical trials. Our results show that drugs resensitizing chemoresistant cells 
are superior to those aimed at triggering apoptosis or increasing the bioavailability of platinum. Our 
results further show that the benefit of using biomarker stratification in clinical trials is dependent on the 
efficacy of the drug and tumor composition. The mathematical framework presented herein is suitable for 
systematically testing various drug combinations and clinical trial designs in solid cancers.
The development of effective treatments for advanced solid cancers has turned out to be more difficult than 
expected, and the current success rate of translating encouraging preclinical results into successful clinical trials 
is low1,2. To increase the success rate, we and others have suggested using a virtual clinical trial (VCT) approach 
to systematically test the effectiveness of new treatment regimens3–5. The VCTs allow for the creation of a large 
in silico cohort of patients, whose collective response to a drug or drug combinations corresponds to real-life 
cohorts. A typical VCT has the advantage of taking longitudinal clinical, radiological, or preclinical data to rap-
idly estimate the effectiveness of treatment modalities.
High-grade serous ovarian cancer (HGSOC) is the most abundant and lethal epithelial ovarian cancer sub-
type, accounting for approximately 80% of the cases with a five-year survival rate of 43%6. The standard-of-care 
(SOC) therapy for metastasized HGSOC consists of debulking surgery and platinum-taxane chemotherapy. Even 
though most of the advanced HGSOC patients respond well to SOC, nearly all patients relapse and develop 
resistance to platinum-based chemotherapy. Thus, identifying effective therapies that can prevent the emergence 
or overcome platinum resistance would potentially improve the outcomes of patients with HGSOC.
Platinum resistance is a complex and multifactorial process7,8. While several mechanisms lead to platinum 
resistance, three main categories are9,10 (1) reduced intake or increased efflux of platinum, leading to reduced 
platinum bioavailability in a cell (pre-target resistance); (2) enhanced DNA repair mechanisms that overcome 
platinum-induced DNA adducts (on-target resistance); and (3) dysfunctional apoptosis machinery (post-target 
resistance). Targeting these major resistance mechanisms is an area of intensive research. For instance, the copper 
influx transporter (CTR1) is a primary platinum uptake transporter, whose high expression correlates with longer 
disease-free intervals and overall survival11. Preclinical data demonstrate that trientine, a copper chelating agent, 
increases platinum uptake through CTR112,13, and early-phase clinical data show evidence that trientine may 
reverse platinum resistance14. Cell cycle regulation is a crucial step in efficient DNA repair15, and Wee1 inhibitors 
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are emerging cell cycle inhibitors that have been successfully combined with platinum. Indeed, preclinical and 
early-phase clinical studies indicate that Wee1 inhibitors are able to resensitize platinum-resistant cells15–17. In 
addition, compounds targeting the apoptosis machinery have been suggested to overcome platinum resistance. 
Downregulation or pharmacological inhibition of the inhibitor of apoptosis protein (IAP) family with birinapant 
resulted in enhanced apoptosis in vitro and prolonged survival time in mice18. Furthermore, an early clinical trial 
suggested that a combination of platinum and birinapant is well-tolerated19.
Previously, we have shown that an HGSOC patient, on average, has five active platinum resistance mecha-
nisms present already at diagnosis5. However, combination treatment where standard-of-care chemotherapy is 
supplemented with targeted drugs for the three most dominant resistant mechanisms would significantly prolong 
patient survival. Accordingly, we hypothesize here that an effective strategy to overcome platinum resistance is 
to combine platinum-based chemotherapy with drugs targeting the three major classes of platinum resistance 
mechanisms; pre-target, on-target, and post-target.
We have developed a mathematical framework to conduct virtual clinical trials (VCTs) during first-line treat-
ment of HGSOC. We modeled novel combinations targeting three major (pre-target, on-target, and post-target) 
classes of platinum resistance, and show that a drug sensitizing resistant cells to platinum is superior to agents 
directly killing the resistant cells. Using VCT approach, we identify the most efficient combinations, and demon-
strate that patient stratification with molecular biomarkers further improves patient outcomes.
Results
Mathematical model describes innate platinum resistance as a multifactorial process. We con-
structed a multitype branching process mathematical model that describes the dynamics of platinum sensitive, 
partially sensitive, and fully resistant cells in advanced HGSOC. The model schematic is presented in Fig. 1A. 
Briefly, we included in the model three main platinum resistance mechanisms: reduced influx/increased efflux of 
platinum (pre-target), enhanced DNA damage response pathway (on-target), and damaged apoptosis machinery 
(post-target), which accumulate during cell division because of (epi)genetic aberrations. Detailed model descrip-
tion and all model assumptions are presented in the Materials and Methods section and Supplementary Text 1. 
All parameter values are listed in Table 1. The model simulation of each virtual HGSOC patient was performed in 
accordance with neoadjuvant chemotherapy (NACT) SOC in HGSOC meaning that two types of interventions 
are included in the simulations: interval debulking surgery and platinum-based chemotherapy. The model simu-
lation is composed of three phases: pre-diagnosis, treatment, and post-treatment as shown in Fig. 1B.
Response to platinum in HGSOC patients is clinically measured using platinum-free interval (PFI) defined as 
the time from last platinum therapy to tumor relapse20. Clinically, the first PFI predicts outcomes and dictates the 
second-line therapeutic approaches for the patients21. Next, we evaluated whether our model of innate platinum 
resistance was able to predict patient outcomes. As shown in Fig. 2, our model accurately estimated PFIs. The 
median PFI of patients in the calibration and validation cohorts equaled six and seven months, respectively, and 
the median PFI for the virtual cohort of 1,000 patients was eight months.
Virtual clinical trial analysis estimates the added value of targeted therapy. We used our math-
ematical model and a VCT approach to evaluate the added value of combining drugs that target the three main 
resistance mechanisms to platinum. We created a virtual cohort of advanced HGSOC patients treated with 
platinum-based chemotherapy alone or a combination of platinum-based chemotherapy together with a drug 
targeting one of three platinum resistance mechanisms. Details of the targeted therapies included in the model are 
explained in Supplementary Text 1, and the VCT approach is schematically depicted in Fig. 1C. Model calibration 
is described in Supplementary Text 4. Model prediction with clinical data from the calibration and validation 
cohorts are shown in Fig. 2.
Our results show that at diagnosis, the tumor is mostly composed of sensitive cells and a small fraction of 
resistant cells (Fig. 3), which explains the observed good initial response in HGSOC. However, our results further 
indicate that after platinum-based chemotherapy, the tumor is mainly composed of cells with one active drug 
resistance mechanism, which undermines the effect of subsequent chemotherapy cycles. There results highlight 
the importance of tumor composition in chemotherapy effectiveness.
We then modeled the combination of platinum-based chemotherapy and trientine, Wee1 inhibitor, or bir-
inapant as examples of drugs targeting the different resistance mechanisms and estimated their effects on PFI 
and tumor composition (Fig. 3). Combining platinum and trientine led to a 99% decrease in tumor burden and 
a PFI of three months longer in comparison to platinum-based chemotherapy alone (p = 0.00004, log-rank test). 
However, trientine caused an enrichment of fully resistant cells compared to the other drugs, which suggests 
that platinum rechallenge after trientine may not have a significant impact. The addition of birinapant decreased 
tumor burden by 99% and improved the PFI by five months (p < 0.00001, log-rank test). The biggest decrease 
in tumor burden (99.99%) and improvement in PFI (19 months, p < 0.00001, log-rank test) was obtained when 
Wee1 inhibitor was combined with platinum. Importantly, combining Wee1 inhibitor to chemotherapy led to a 
larger retainment of platinum-sensitive cancer cells (29%) compared to the other combination therapies (3% and 
2% for trientine and birinapant, respectively), consistent with the PFI benefit from this combination.
The results from combining simultaneously two and three drugs are presented in Supplementary Fig. 3. 
Briefly, the best combination of two targeted drugs with the platinum-based chemotherapy was Wee1 inhibitor 
and birinapant, which led to a median PFI of 56 months. Birinapant combined with trientine led to the short-
est median PFI of 17 months. When combining all three drugs with platinum, the median PFI increased to 59 
months, and approximately 85% of the remaining cancer cells were sensitive to platinum-based chemotherapy.
The effect of targeting the dominant platinum resistance mechanism depends on drug efficacy and tumor 
composition. The effect of a targeted drug is hypothesized to be improved when the choice of a drug is guided 
using a molecular biomarker. We tested this hypothesis using the MSCTS approach.
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Figure 1. Schematics of the mathematical model and virtual clinical trial simulations framework. Panel (A) We 
developed a mathematical model that consists of three main platinum resistance mechanisms, pre-target, on-target, 
and post-target resistance. Accordingly, this gives rise to eight types of cancer cells that are referred to as sensitive (no 
resistance mechanisms active), partially resistant (one or two resistance mechanisms active), and fully resistant (all 
three resistance mechanisms active). All cancer cells proliferate at rate b and die at rate d (only shown for sensitive cells). 
Panel (B) The model simulation starts from a single sensitive cancer and the tumor progresses until diagnosis (pre-
treatment phase). We modeled HGSOC patients undergoing neoadjuvant chemotherapy (NACT) standard-of-care 
(SOC) treatment for HGSOC, which consists of NACT followed by interval debulking surgery (IDS) and adjuvant 
chemotherapy (ADJ). After the treatment phase, the model is simulated until the first recurrence (post-treatment 
phase. Panel (C). The simulations contain randomized controlled trial simulations (RCTSs) and molecularly stratified 
controlled trial simulations (MSCTSs). An RCTS estimates the added value of a drug in a general HGSOC patient cohort 
and corresponds to traditional clinical trials where patients are not stratified based on a molecular biomarker. An MSCTS 
estimates the added value of using a molecular biomarker that stratifies patients according to their dominant drug 
resistance mechanism.
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We tested the benefit of choosing one targeted drug based on a biomarker for the dominant resistance mech-
anism and combining it with the platinum-based chemotherapy (Fig. 4 and Table 2). The benefit of choosing 
patients positive to trientine was four months in comparison to patients without the positive marker (p < 0.0001, 
log-rank test). For birinapant, the relative PFI benefit was three months. Thus, adding biomarker-based patient 
stratification was highly beneficial for trientine and birinapant (p < 0.00001, log-rank test). For Wee1 inhibitor, 
the relative PFI benefit was one month (18 months vs. 17 months, p = 0.02, log-rank test). However, combining 
Wee1 to chemotherapy in a biomarker-unselected population was still superior to the biomarker-selected treat-
ments combining trientine (p < 0.0001) or birinapant (p < 0.0001) with chemotherapy.
Discussion
A major reason for the low success rate in translating preclinical results into successful clinical trials is that in vitro 
and in vivo models rarely capture the variations in treatment responses seen in real-life patient cohorts. Here, we 
have developed a mathematical model to create virtual patient cohorts that enabled us to test the effectiveness 
of targeted therapy to overcome platinum resistance. Our framework consists of (1) a stochastic model of innate 
platinum resistance, (2) a method for the estimation of relative drug efficacy based on three levels of evidence, (3) 
a model of targeted therapy, and (4) a simulator of virtual clinical trials.
In our approach, we did not explicitly consider toxicity when combining the drugs, which will need addi-
tional clinical consideration. Thus, in our case study we chose targeted drugs that have been well tolerated in 
Symbol Value Unit Description Reference
b 0.667 1day Division rate Taken from27
d 0.661
1
day Death rate Taken from29
u 10−5 1cell division Transition rate Taken from5
M 3.959·1011 # of cells Average tumor burden at diagnosis Taken from5
Mrelapse 109 # of cells Tumor burden at recurrence Taken from30
dchemotherapy 0.856 — Average chemotherapy effect on sensitive cells
Estimated from a calibration 
cohort from5
α1 0.02 —
Weight of chemotherapy effects on cells with one 
resistance mechanism
Estimated from a calibration 
cohort from5
α2 0.01 —
Weight of chemotherapy effects on cells with two 
resistance mechanisms
Estimated from a calibration 
cohort from5
β 2 cell-log kill Fraction of cells removed by surgery Taken from5
Table 1. Standard parameters and their values for the platinum resistance mathematical model. “—” represents 
dimensionless unit.
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Figure 2. Model calibration. Estimated survival values for the calibration, validation, and simulated cohorts. 
Kaplan-Maier analysis was performed for the calibration and validation cohorts based on platinum-free interval 
(PFI) values. The mathematical model is capable of creating HGSOC cohorts that closely resemble real-life 
cohorts. Calibration of the targeted treatment is presented in Supplementary Fig. 2.
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combination with platinum in clinical trials. Furthermore, we focused on modeling cancer cell evolution and 
response to chemotherapy, and interaction with the tumor microenvironment, which plays an important but 
poorly understood role in chemoresistance, will be conducted in future work. The weighting of evidence from 
in vitro experiments, in vivo experiments and clinical trial experiments for drug efficacy is based on the fact that 
only a small fraction of drugs that successfully eradicate tumor cells in vitro make it to the clinical trials and only 1 
out of 50 drugs entering clinical trials are successful, which indicates that the data arising from preclinical models 
have a lower likelihood of success in clinical translation. The evidence weights can be modified whenever new 
preclinical or clinical data arise on single-agent therapies.
We tested our framework by estimating the added value of combining platinum with trientine, Wee1 inhibitor, 
and birinapant. Our results indicate that targeting one resistance mechanism with platinum-based chemother-
apy increases PFI by several months. The most effective drug with platinum-taxane was Wee1 inhibitor, which 
tripled the PFI as compared to SOC. Moreover, the residual tumor after Wee1 inhibitor consisted of a large frac-
tion of platinum-sensitive cancer cells, which predicts that the subsequent platinum-based chemotherapy cycles 
will be effective. Our results suggest that the class of targeted drugs that resensitize chemoresistant cells is more 
effective than drugs aimed at triggering apoptosis or increasing the bioavailability of platinum. This is in line 
with promising results from the use of Ataxia telangiectasia and Rad3-related (ATR) inhibitors in resensitizing 
platinum-resistant cancers22.
Molecular biomarkers are increasingly used to stratify patients in clinical trials, such as in SHIVA and 
NCI-MATCH23,24. We used the modeling framework to estimate the benefit of using molecular markers in strati-
fying patients. Our results suggest that the two key factors affecting the survival benefit of a stratified trial are the 
efficacy of the drug and tumor composition. The most potent drug in our simulation, Wee1 inhibitor, had virtu-
ally identical effects in stratified and non-stratified patient cohorts, whereas trientine and birinapant benefited 
from stratification. The reason for this is that the total relative efficiency of the Wee1 inhibitor is estimated to be 
Figure 3. The added value of adding one platinum resistance targeting drug to platinum-taxane treatment. The 
waffle plots illustrate the fraction of sensitive, partially, and fully resistant cells in tumors. Black circles represent 
tumor burden after primary treatment relative to the tumor burden after platinum-based chemotherapy alone. 
The number below the waffle plots is the median PFI. Kaplan-Meier plots of PFI for each combination therapy 
(red line) compared to chemotherapy alone (blue line). The graphs were compared using log-rank test. Adding 
Wee1 inhibitor to platinum-based chemotherapy results in a PFI of 26 months, which is 19 months more than 
with the SOC. Furthermore, after adding Wee1 inhibitor, the residual tumor contains a sizable fraction of 
platinum-sensitive cells, which increases the probability of a successful platinum rechallenge in the subsequent 
treatment cycles. All two- and three-drug combination results are shown in Supplementary Fig. 3.
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more than two times greater than that of trientine and birinapant. Thus, the Wee1 inhibitor very effectively kills 
cancer cells with an active on-target resistance mechanism. Although an on-target resistance mechanism may 
not be dominant in many cases, its fraction is still so large that the Wee1 inhibitor remains a very potent option 
even in a biomarker-unselected patient population. In contrast, in the less potent trientine and birinapant com-
binations, tumor-free time was clearly improved with patient stratification. This indicates that in the biomarker 
stratified trials, the estimated effect of the tested drug on the tumor composition should be, if possible, taken into 
account in the trial planning phase.
The herein presented mathematical framework is suitable for systematically testing various drug combina-
tions and clinical trial designs in solid cancers. The major advantage of the framework is that it enables estimat-
ing the efficacy of a drug combination in an inexpensive and rapid manner, and thus facilitates the design of 
combination-therapy clinical trials.
Figure 4. Molecularly stratified clinical trials simulations. The waffle plots illustrate tumor composition after 
primary treatment and the black circle the tumor burden. In the right column, Kaplan-Meier plots showing the 
comparison of the biomarker-positive and biomarker-negative VCT arms.
Drug
Biomarker 
negative
Biomarker 
positive
Relative 
benefit
Trientine 7 11 4
Wee1 inhibitor 17 18 1
Birinapant 8 11 3
Table 2. Molecularly stratified clinical trial simulations. Median PFI values for two treatment arms in MSCTS 
and relative benefit of patient stratification. The values are presented in months.
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Methods
Description of calibration and validation cohort. Clinical data for HGSOC patients were collected 
as explained in5. Briefly, the first cohort included 62 advanced stage III–IV HGSOC patients treated at Turku 
University Central Hospital from 2009 to 2016 and was used as a calibration cohort. The patients participating in 
the study gave their informed consent, and the study and the use of all clinical material have been approved by (i) 
The Ethics Committee of the Hospital District of Southwest Finland (ETMK): ETMK 53/180/2009 × 238 and (ii) 
National Supervisory Authority for Welfare and Health (Valvira): DNRO 6550/05.01.00.06/2010 and STH507A, 
and all experiments were performed in accordance with the guidelines and regulations. All patients in this cohort 
were evaluated as inoperable at the time of diagnosis and were referred to neoadjuvant chemotherapy (NACT) 
before interval debulking surgery (IDS).
To reliably estimate the effects of chemotherapy in HGSOC patients, we calculated total metabolic tumor vol-
ume (MTV) as the sum volume of all the tumor lesions from 18F-FDG-PET/CT images before and after NACT5. 
This change in tumor burden was used for the model construction and calibration. The second cohort was used 
as an independent validation cohort, and it included 170 patients from The Cancer Genome Atlas (TCGA). The 
validation cohort was filtered from a cohort of 489 HGSOC patients available in TCGA, using similar criteria for 
patient characteristics as in the calibration cohort, including patients with (i) advanced HGSOC (grade >1, stage: 
IIIb–IV), (ii) an indication of attempted surgical debulking, that is, information available on the residual disease, 
and (iii) treatment by platinum-based chemotherapy alone or in combination in the first-line setting (for more 
detailed explanation see5). We used platinum-free interval (PFI), defined as the time from last platinum-based 
chemotherapy to tumor relapse as the primary outcome measure, and secondary outcome measures were tumor 
burden and its composition.
Mathematical model of innate resistance to platinum and targeted therapy. Our mathematical 
model describes tumor growth and the evolution of platinum resistance as a multitype branching process25,26. 
Innate platinum resistance is a multifactorial process. According to the mechanisms of action, it can be broadly 
divided into three main classes: pre-target, on-target, and post-target resistance. The model includes these three 
main classes of drug resistance mechanisms. The schematic of the model is shown in Fig. 1A, where each subclone 
is defined with three digits: 0 (1) mean absence (presence) of given platinum resistance mechanism.
Most of the parameter values are taken from previous studies5,27, whereas the parameters u, α1, and α2 were 
fitted to the clinical data from the calibration cohort as described in the Supplementary Text 4. In short, we took 
100 values for u between 10−4 to 10−8 and 101 values for α1 and α2 between 0 and 1, leading to 1,020,100 param-
eter combinations. Next, we performed a grid search by performing a PFI analysis for each parameter combina-
tion, and we checked the agreement of the model predictions with the clinical data from the calibration cohort 
by calculating the root-mean-square error (RMSE). Finally, we chose the combination of u, α1, and α2 that had 
the smallest RMSE.
In addition to modeling innate platinum resistance, we also modeled targeted therapy. That is, we included 
three drugs: trientine, Wee1 inhibitor, and birinapant which target pre-, on- and post-target platinum resistance 
respectively. Details of our mathematical model and inclusion of targeted therapy is described in Supplementary 
Text 1 and presented schematically in Supplementary Fig. 1. The model was implemented and simulated using 
MATLAB environment. The code of the model simulator is freely available (https://github.com/EmiliaKo/
vctsInOVCA).
Drug efficacy estimation for combinatorial treatment analysis. To estimate the relative efficacy (E) 
of targeted therapy, we searched and evaluated the relative efficacies in comparison to platinum alone reported 
in the literature at three levels of evidence: in vitro (I), in vivo (V), and clinical trial (C). We calculated the efficacy 
of the targeted therapies in relation to platinum. Thus, a drug with 100% relative efficacy has an identical effect 
as platinum.
The relative efficacy of a drug is extracted from the literature as a reported reduction of tumor burden in 
comparison to platinum-based chemotherapy. As in vitro drug efficacy is often higher than observed in vivo or 
clinical trials, we estimated a drug’s relative efficacy as follows. The relative efficacy of a drug in a clinical trial is 
considered 2.5 times more important than in vitro, and in vivo relative efficacy is weighted as 60% of the evidence 
from clinical trials. Thus, total relative efficacy (E) is calculated as:
= . ⋅ + . ⋅ + .E I V C0 2 0 3 0 5
The values for E, I, V, and C are listed in Supplementary Table 1. The relative efficacies are used in the model 
as a relative reduction in tumor burden after primary treatment in comparison to platinum-based chemotherapy 
alone. The estimated total relative efficacy for trientine was 41%, for Wee1 inhibitor 85%, and for birinapant 35%.
Randomized and molecularly stratified virtual clinical trial simulations. We designed two types of 
VCTs: a randomized controlled trial simulation (RCTS) without molecular marker-guided patient selection and 
a molecularly stratified controlled trial simulation (MSCTS). We first performed a RCTS to estimate the effective-
ness of the targeted therapies in non-selected HGSOC patients. Next, we performed a MSCTS to assess the puta-
tive improvement of PFI when a biomarker for the dominant resistance mechanism was used to select patients.
Both types of clinical trial simulations were performed by simulating the course of tumor progression 
(Fig. 1B). In addition, primary treatment was simulated according to the SOC in HGSOC. That is, simulation of 
the treatment phase was performed according to National Comprehensive Cancer Network (NCCN) guidelines, 
which suggest platinum-taxane chemotherapy and debulking surgery as the first-line treatment28. Before starting 
the simulations, a virtual patient was defined with two model parameters (Mdiagnosis and dchemotherapy) and sampling 
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them from the log-normal probability distribution. Next, the model simulation started with a single sensitive cell 
until the time of diagnosis, which is defined as the time when tumor burden reaches Mdiagnosis cells (pre-treatment 
phase). After diagnosis, primary treatment composed of three cycles of NACT, IDS, and three cycles of adjuvant 
chemotherapy (ADJ) was administered (treatment phase). The model was simulated until the first relapse, and 
PFI was used as the outcome (post-treatment phase).
The RCTS was performed by assigning virtual randomly selected HGSOC patients to one of two groups: 
platinum-based chemotherapy alone or platinum-based chemotherapy with a drug targeting a platinum resist-
ance mechanism. Next, each virtual HGSOC patient in the cohort was simulated. To each of the groups in the 
RCTS, we assigned 1,000 virtual patients, leading to a total cohort of 2,000 virtual patients. Finally, patient’s out-
come was measured using PFI. In addition, the tumor composition after primary treatment was measured and 
compared.
In the MSCTS, virtual patients were stratified using molecular biomarkers. Here, we assumed that a reliable 
biomarker existed for each of the platinum resistance mechanisms included in the model. In the simulations, 
we assumed that the biomarkers were ideal (i.e., their sensitivities and specificities were 100%). We used the 
biomarkers as follows. First, 1,000 virtual patients were assigned to the biomarker positive and the biomarker 
negative groups, according to the dominant mechanisms. For instance, for Wee1 inhibitor, the biomarker positive 
group consisted of patients with on-target platinum resistance as the dominant resistance mechanism, while the 
biomarker negative group contained patients with pre-target or post-target resistance as their dominant mecha-
nisms. The patients in both groups were treated with platinum-based chemotherapy and Wee1 inhibitor, followed 
by Kaplan-Meier analysis and average tumor composition.
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files). The model simulator is available in GIThub repository (https://github.com/EmiliaKo/
vctsInOVCA).
Received: 8 May 2019; Accepted: 18 November 2019;
Published: xx xx xxxx
References
 1. Lieu, C. H., Tan, A.-C., Leong, S., Diamond, J. R. & Eckhardt, S. G. From bench to bedside: lessons learned in translating preclinical 
studies in cancer drug development. JNCI J. Natl. Cancer Inst. 105, 1441–1456 (2013).
 2. Kim, E., Rebecca, V. W., Smalley, K. S. M. & Anderson, A. R. A. Phase i trials in melanoma: A framework to translate preclinical 
findings to the clinic. Eur. J. Cancer 67, 213–222 (2016).
 3. Harrison, R. L. et al. A virtual clinical trial of FDG-PET imaging of breast Cancer: effect of variability on response assessment. 
Transl. Oncol. 7, 138–146 (2014).
 4. Han, K. et al. Simulations to predict clinical trial outcome of Bevacizumab Plus chemotherapy vs. chemotherapy alone in patients 
with first-line gastric cancer and elevated plasma VEGF-A. CPT Pharmacometrics Syst. Pharmacol. 5, 352–358 (2016).
 5. Kozłowska, E. et al. Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer. 
Cancer Res. 78, 4036–4044 (2018).
 6. Torre, L. A. et al. Ovarian cancer statistics, 2018. CA. Cancer J. Clin. 68, 284–296 (2018).
 7. Colombo, P.-E. et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit. Rev. Oncol. 
Hematol. 89, 207–16 (2014).
 8. Tapia, G. & Diaz-padilla, I. Molecular Mechanisms of Platinum Resistance in Ovarian Cancer. Obstet. Gynecol., https://doi.
org/10.5772/55562 (2013).
 9. Galluzzi, L. et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 5, e1257 (2014).
 10. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869–1883 (2012).
 11. Kilari, D., Guancial, E. & Kim, E. S. Role of copper transporters in platinum resistance. World J. Clin. Oncol. 7, 106–13 (2016).
 12. Liang, Z. D. et al. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol. Cancer Ther. 11, 
2483–2494 (2012).
 13. Brown, D. P. G., Chin-Sinex, H., Nie, B., Mendonca, M. S. & Wang, M. Targeting superoxide dismutase 1 to overcome cisplatin 
resistance in human ovarian cancer. Cancer Chemother. Pharmacol. 63, 723–730 (2009).
 14. Fu, S. et al. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest. 
New Drugs 32, 465–472 (2014).
 15. Hirai, H. et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-
damaging agents. Mol. Cancer Ther. 8, 2992–3000 (2009).
 16. Osman, A. A. et al. Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head 
and Neck Cancer through Mitotic Arrest Followed by Senescence. Mol. Cancer Ther. 14, 608–619 (2015).
 17. Leijen, S. et al. Phase II study of Wee1 inhibitor AZD1775 plus carboplatin in patients with tp53-mutated ovarian cancer refractory 
or resistant to first-line therapy within 3 months. J. Clin. Oncol. 34, 4354–4361 (2016).
 18. Janzen, D. M. et al. An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian 
cancer. Nat. Commun. 6, 7956 (2015).
 19. Noonan, A. M. et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in 
women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 122, 588–597 (2016).
 20. Colombo, N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. Eur. J. Cancer, Suppl. 12, 
7–12 (2014).
 21. Plaxe, S. C. et al. NCCN Guidelines Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. (2017).
 22. Mei, L., Zhang, J., He, K. & Zhang, J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J. 
Hematol. Oncol. 12, 43 (2019).
 23. Tourneau, C. L. et al. Molecularly targeted therapy based on tumour molecular profi ling versus conventional therapy for advanced 
cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. 16 (2015).
 24. Barroilhet, L. & Matulonis, U. The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecol. Oncol. 148, 585–590 
(2018).
 25. Durrett, R. Branching process models of cancer., https://doi.org/10.1007/978-3-319-16065-8_1, (Springer International Publishing, 
2015).
9Scientific RepoRtS |         (2019) 9:18678  | https://doi.org/10.1038/s41598-019-55068-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
 26. Kimmel, M. & Axelrod, D. E. Branching Processes in Biology. 19, (Springer-verlag New York, 2002).
 27. Panetta, J. C. A mathematical model of breast and ovarian cancer treated with paclitaxel. Math. Biosci. 146, 89–113 (1997).
 28. Armstrong, D. K. New Therapies for Ovarian Cancer. J. Natl. Compr. Cancer Netw. 16, 632–635 (2018).
 29. Brown, P. O. & Palmer, C. The preclinical natural history of serous ovarian cancer: Defining the target for early detection. PLoS Med. 
6, e1000114 (2009).
 30. Del Monte, U. Does the cell number 109 still really fit one gram of tumor tissue? Cell Cycle 8, 505–506 (2009).
Acknowledgements
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme 
under grant agreement No. 66740, the Academy of Finland, the Sigrid Jusélius Foundation, Finnish Cancer 
Associations and by National Science Centre, Poland (https://ncn.gov. pl), grant DEC 2016/21/B/ST7/02241. 
The results published here are in part based upon data generated by TCGA managed by the NCI and NHGRI. 
Information about TCGA can be found at http://cancergenome.nih.gov.
Author contributions
Conceived the project: E.K., A.F. and S.Ha. Conceived the mathematical model and simulations: E.K. Performed 
all model simulations: E.K. Analysis of results: A.F., E.K., J.H., S.Hi. and S.Ha. Developed method to estimate drug 
combination efficacy: A.F. and.E.K. Supervised the project: A.F. and S.Ha. Wrote manuscript: E.K., S.Ha. and A.F. 
Critically edited and approved the manuscript: A.F., E.K., J.H., S.Ha., S.Hi. and T.V.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-55068-z.
Correspondence and requests for materials should be addressed to A.F. or S.H.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
